JP4545440B2 - 疾患および損傷の処置のための一酸化窒素ドナー - Google Patents

疾患および損傷の処置のための一酸化窒素ドナー Download PDF

Info

Publication number
JP4545440B2
JP4545440B2 JP2003557275A JP2003557275A JP4545440B2 JP 4545440 B2 JP4545440 B2 JP 4545440B2 JP 2003557275 A JP2003557275 A JP 2003557275A JP 2003557275 A JP2003557275 A JP 2003557275A JP 4545440 B2 JP4545440 B2 JP 4545440B2
Authority
JP
Japan
Prior art keywords
cells
rats
treatment
sildenafil
brain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2003557275A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005514406A5 (https=
JP2005514406A (ja
Inventor
マイケル チョップ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Henry Ford Health System
Original Assignee
Henry Ford Health System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Henry Ford Health System filed Critical Henry Ford Health System
Publication of JP2005514406A publication Critical patent/JP2005514406A/ja
Publication of JP2005514406A5 publication Critical patent/JP2005514406A5/ja
Application granted granted Critical
Publication of JP4545440B2 publication Critical patent/JP4545440B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2003557275A 2002-01-04 2003-01-06 疾患および損傷の処置のための一酸化窒素ドナー Expired - Fee Related JP4545440B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34547802P 2002-01-04 2002-01-04
PCT/US2003/000323 WO2003056899A2 (en) 2002-01-04 2003-01-06 Nitric oxide donors for treatment of disease and injury

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009181759A Division JP2009256374A (ja) 2002-01-04 2009-08-04 疾患および損傷の処置のための一酸化窒素ドナー

Publications (3)

Publication Number Publication Date
JP2005514406A JP2005514406A (ja) 2005-05-19
JP2005514406A5 JP2005514406A5 (https=) 2009-09-24
JP4545440B2 true JP4545440B2 (ja) 2010-09-15

Family

ID=23355218

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2003557275A Expired - Fee Related JP4545440B2 (ja) 2002-01-04 2003-01-06 疾患および損傷の処置のための一酸化窒素ドナー
JP2009181759A Pending JP2009256374A (ja) 2002-01-04 2009-08-04 疾患および損傷の処置のための一酸化窒素ドナー

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2009181759A Pending JP2009256374A (ja) 2002-01-04 2009-08-04 疾患および損傷の処置のための一酸化窒素ドナー

Country Status (9)

Country Link
US (2) US20050143388A1 (https=)
EP (1) EP1469852A4 (https=)
JP (2) JP4545440B2 (https=)
CN (1) CN1638775A (https=)
AU (1) AU2003210447B2 (https=)
CA (1) CA2471147C (https=)
IL (1) IL162850A0 (https=)
WO (1) WO2003056899A2 (https=)
ZA (1) ZA200405507B (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007010337A2 (de) * 2005-07-15 2007-01-25 Proxomed Medizintechnik Gmbh Verwendung von phosphodiesterase typ 5-hemmern für die prävention und behandlung von adipositas, sowie abgabesysteme für dieselben
WO2008020864A2 (en) * 2005-11-14 2008-02-21 The Trustees Of Columbia University In The City Of New York Imaging correlates of neurogenesis with mri
US8841300B2 (en) 2006-10-02 2014-09-23 Jerry M. Held Treatment for Parkinson's disease—combination high dose serotonergic synaptic reuptake inhibitor with phosphodiesterase inhibitor
CA2687679A1 (en) * 2007-05-18 2008-11-27 Vivus, Inc. Novel compositions comprising a phosphodiesterase-5 inhibitor and their use in methods of treatment
WO2009046377A2 (en) * 2007-10-04 2009-04-09 Medistem Laboratories, Inc. Compositions and methods of stem cell therapy for autism
WO2009059271A1 (en) * 2007-11-02 2009-05-07 University Of Miami Diagnosis and treatment of cardiac disorders
MX361539B (es) 2012-04-25 2018-12-10 Takeda Pharmaceuticals Co Compuesto heterociclico nitrogenado.
EP2873669A4 (en) 2012-07-13 2015-11-25 Takeda Pharmaceutical HETEROCYCLIC CONNECTION
JP6338601B2 (ja) * 2013-03-01 2018-06-06 フンダシオン パラ ラ インベスティガシオン メディカ アプリカダ ホスホジエステラーゼとヒストンデアセチラーゼの二重阻害剤としての新規な化合物
EP2975031A4 (en) 2013-03-14 2017-04-19 Takeda Pharmaceutical Company Limited Heterocyclic compound
JP6427491B2 (ja) 2013-07-03 2018-11-21 武田薬品工業株式会社 複素環化合物
ES2950424T3 (es) 2013-07-03 2023-10-09 Takeda Pharmaceuticals Co Compuesto de amida
US10297661B2 (en) * 2017-06-30 2019-05-21 Taiwan Semiconductor Manufacturing Co., Ltd. High voltage resistor device
EP4450072A4 (en) * 2021-12-14 2026-02-18 Zhenao Jinyinhua Pharmaceutical USE OF SILDENAFIL OR A SALT THEREOF IN THE PREPARATION OF A MEDICINE FOR THE PREVENTION OR TREATMENT OF ISCHEMIC BRAIN INJURY
TWI879058B (zh) * 2023-08-31 2025-04-01 未來新藥股份有限公司 Pde5抑制劑組合於促進神經突生長之新穎用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2224195A (en) * 1994-04-15 1995-11-10 Masaomi Iyo Medicinal composition for treating tardive dyskinesia and utilization thereof
US5827740A (en) * 1996-07-30 1998-10-27 Osiris Therapeutics, Inc. Adipogenic differentiation of human mesenchymal stem cells
EP1006798A4 (en) * 1996-09-05 2003-03-05 Massachusetts Inst Technology COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISORDERS AND NEURODEGENERATIVE DISEASES
US6043223A (en) * 1997-11-12 2000-03-28 The Regents Of The University Of California Enhanced opening of abnormal brain tissue capillaries
DE19834507A1 (de) * 1998-07-31 2000-02-03 Hexal Ag Pharmazeutische, wasserlösliche Tablettenformulierung zur Anwendung von Sildenafil
JP2002544234A (ja) * 1999-05-14 2002-12-24 ヘンリー フォード ヘルス システム 発作の処置のための骨髄移植
IL147112A0 (en) * 1999-06-14 2002-08-14 Ford Henry Health System Nitric oxide donors for inducing neurogenesis
US6075028A (en) * 1999-09-23 2000-06-13 Graham; Richard Method of treating Tourette's syndrome and related CNS disorders
IL139073A0 (en) 1999-10-21 2001-11-25 Pfizer Treatment of neuropathy
US6271228B1 (en) * 2000-04-28 2001-08-07 Pfizer Inc. Blood pressure stabilization during hemodialysis
ATE526020T1 (de) * 2000-08-10 2011-10-15 Cold Spring Harbor Lab Gesteigertes kognitives training

Also Published As

Publication number Publication date
AU2003210447A1 (en) 2003-07-24
JP2009256374A (ja) 2009-11-05
US20050143388A1 (en) 2005-06-30
EP1469852A2 (en) 2004-10-27
WO2003056899A2 (en) 2003-07-17
AU2003210447B2 (en) 2008-02-07
CA2471147C (en) 2010-08-10
ZA200405507B (en) 2005-05-25
JP2005514406A (ja) 2005-05-19
WO2003056899A3 (en) 2003-11-27
EP1469852A4 (en) 2009-12-02
US20120009152A1 (en) 2012-01-12
WO2003056899A9 (en) 2004-04-15
CN1638775A (zh) 2005-07-13
CA2471147A1 (en) 2003-07-17
IL162850A0 (en) 2005-11-20

Similar Documents

Publication Publication Date Title
JP2009256374A (ja) 疾患および損傷の処置のための一酸化窒素ドナー
Li et al. Exosomes derived from mesenchymal stem cells attenuate inflammation and demyelination of the central nervous system in EAE rats by regulating the polarization of microglia
Xin et al. MSCs-extracellular vesicles attenuated neuroinflammation, synapse damage and microglial phagocytosis after hypoxia-ischemia injury by preventing osteopontin expression
Bogunovic et al. Identification of a radio-resistant and cycling dermal dendritic cell population in mice and men
US11123376B2 (en) Method of treatment
JP7699378B2 (ja) 軽度の認知障害、抑うつ、および精神障害の治療のための治療薬組成物およびその使用方法
US20100322907A1 (en) Expansion of Hematopoietic Stem Cells
US20210169939A1 (en) Extracellular vesicles and their uses
US20050158397A1 (en) Materials from bone marrow stromal cells for use in forming blood vessels and producing angiogenic and trophic factors
ES2418433T3 (es) Modulación de receptores de catecolaminas
JP2019524824A (ja) 神経障害を処置するための間葉系細胞由来エキソソーム
JP2010504083A5 (https=)
US20100004244A1 (en) Use of cb2 receptor agonists for promoting neurogenesis
Li et al. Lycium barbarum polysaccharide inhibits ischemia-induced autophagy by promoting the biogenesis of neural stem cells-derived extracellular vesicles to enhance the delivery of miR-133a-3p
EP3964219A1 (en) Pharmaceutical composition for treating sepsis or systemic inflammatory response syndrome, comprising isolated mitochondria as active ingredient
KR102622408B1 (ko) Opa1 억제에 의한 조골세포 활성화를 통한 골형성 촉진 유도용 또는 골질환 치료용 조성물
JP5500773B2 (ja) 副甲状腺ホルモン受容体の活性化並びに幹細胞及び前駆細胞の増殖
Corpuz Role of Macrophages in Ocular Surface Fibrosis
AU2024206401A1 (en) Megakaryocyte derivatives for treatment of dry eye diseases
WO2010060928A2 (en) Compositions for the treatment of ischemic tissue damage
HRP20040135A2 (en) Osteogenic growth oligopeptides as stimulants of hematoiesis

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060131

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090204

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090430

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090512

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090603

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090610

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090703

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090714

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20090804

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090914

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091209

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091216

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100113

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100120

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100212

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100315

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100601

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100630

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130709

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees